Drugs / CLN-617
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06035744 | Dec 2023 → Jun 2026 | neoplasm | Cullinan Therapeutics Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-27 | Cullinan Therapeutics Inc. | Regulatory Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines cullinantherapeutics.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-14 | Cullinan Therapeutics Inc. | Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines cullinantherapeutics.com ↗ |
| 2023-03-27 | Cullinan Therapeutics Inc. | Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines cullinantherapeutics.com ↗ |
| 2023-03-14 | Cullinan Therapeutics Inc. | Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting cullinantherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLN-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06035744 ↗ |
| Modality | Protein / enzyme biologic | “CLN-617 is a single-chain fusion protein comprised of IL2, leukocyte-associated immunoglobulin-like receptor 2 (LAIR2), human serum albumin (HSA), and IL12.” PMID 38842347 ↗ Aug 2024 |
| Route | Other | “intratumoral (IT) injection” PMID 38842347 ↗ Aug 2024 |